Amicus (FOLD) AI Stock Analysis

• Market Cap: $4.42B
• Dividend Yield: N/A
• Average Volume (3M): 14.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: 21.28%
• EPS Growth: 87.30%
• Country: US
• Employees: 499
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 309,309,360
• 10 Day Avg. Volume: 9,734,267
• 30 Day Avg. Volume: 14,035,287
• PEG Ratio: 0.79
• Price to Book (P/B): 14.78
• Price to Sales (P/S): 5.43
• P/FCF Ratio: -76.57
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 4.38
• Enterprise Value/Gross Profit: 4.90
• Enterprise Value/Ebitda: 44.29
• 1Y Price Target: $14.25
• Price Target Upside: -0.35% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: $16.00 ▲(11.89% Upside)

Amicus Therapeutics' stock is bolstered by strong technical momentum and positive earnings call sentiment. The acquisition by BioMarin further enhances its outlook. However, financial performance and valuation concerns temper the overall score.

Positive Factors

Revenue Growth

The consistent revenue growth reflects strong demand for Amicus' therapies, indicating successful market penetration and product adoption.

Strategic Acquisition

The acquisition by BioMarin promises strategic benefits, including revenue growth and market exclusivity extensions, enhancing long-term business prospects.

Market Expansion

Expanding market access through new pricing and reimbursement agreements supports long-term revenue growth and global presence.

Negative Factors

High Leverage

High leverage poses financial risks, potentially limiting financial flexibility and increasing vulnerability to economic downturns.

Cash Flow Challenges

Negative cash flow growth suggests difficulties in generating sufficient cash from operations, impacting long-term sustainability.

Profitability Challenges

Negative net profit margin indicates ongoing challenges in achieving profitability, which may hinder long-term financial health.

Amicus Business Overview & Revenue Model

Company Description

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Amicus generates revenue primarily through the commercialization of its approved therapies, such as Galafold (migalastat), which is designed to treat Fabry disease. The company also earns revenue through collaborations and licensing agreements with larger pharmaceutical firms, which may involve upfront payments, milestone payments, and royalties on product sales. Additionally, Amicus may receive funding from government grants or research contracts aimed at supporting the development of its pipeline products. Strategic partnerships with other biopharmaceutical companies can further enhance its revenue streams by providing shared resources and expanding market access for its therapies.

Amicus Financial Statement Overview

Summary

Amicus shows strong revenue growth and gross profit margins, but low net profit margins and high leverage pose financial risks. Cash flow challenges are evident, though free cash flow covers net income.

Income Statement

Amicus has shown a positive trend in revenue growth with a 4.82% increase in the TTM period. The gross profit margin remains strong at approximately 89.77%, indicating efficient cost management. However, the net profit margin is relatively low at 3.32%, suggesting limited profitability. The EBIT and EBITDA margins are modest, reflecting operational challenges.

Balance Sheet

The company has a high debt-to-equity ratio of 1.92, indicating significant leverage, which could pose financial risks. Return on equity is positive at 9.67%, showing some profitability for shareholders. The equity ratio is moderate, suggesting a balanced asset structure but with potential risk due to high debt levels.

Cash Flow

Amicus's free cash flow growth is negative, indicating cash flow challenges. The operating cash flow to net income ratio is negative, reflecting inefficiencies in converting income to cash. However, the free cash flow to net income ratio is slightly above 1, indicating that free cash flow covers net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	598.70M	528.29M	399.36M	329.23M	305.51M	260.89M
Gross Profit	535.61M	475.35M	362.03M	290.63M	271.05M	229.84M
EBITDA	59.27M	29.39M	-92.08M	-199.58M	-202.87M	-242.98M
Net Income	-14.06M	-56.11M	-151.58M	-236.57M	-250.46M	-276.85M
Balance Sheet
Total Assets	868.81M	785.03M	777.88M	724.17M	905.14M	886.52M
Cash, Cash Equivalents and Short-Term Investments	263.84M	249.95M	286.20M	293.60M	482.50M	483.27M
Total Debt	442.82M	443.64M	445.06M	452.12M	440.13M	441.73M
Total Liabilities	638.39M	590.99M	617.71M	601.12M	597.77M	600.14M
Stockholders Equity	230.42M	194.04M	160.17M	123.05M	307.37M	286.38M
Cash Flow
Free Cash Flow	9.69M	-37.44M	-76.53M	-170.34M	-206.38M	-236.52M
Operating Cash Flow	12.98M	-33.89M	-69.09M	-166.57M	-202.49M	-233.29M
Investing Cash Flow	-60.33M	-560.00K	98.06M	92.32M	78.76M	-13.58M
Financing Cash Flow	-12.32M	5.12M	61.68M	-7.46M	212.07M	262.86M

Amicus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOLD, the sentiment is Positive. The current price of 14.3 is above the 20-day moving average (MA) of 12.74, above the 50-day MA of 10.74, and above the 200-day MA of 7.96, indicating a bullish trend. The MACD of 1.18 indicates Negative momentum. The RSI at 90.58 is Negative, neither overbought nor oversold. The STOCH value of 75.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FOLD.

Amicus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPRX	83 Outperform	$2.78B	13.26	27.52%	―	25.56%	44.42%
FOLD	73 Outperform	$4.42B	-319.91	-6.87%	―	21.28%	87.30%
TVTX	56 Neutral	$3.20B	-33.45	-410.78%	―	114.22%	77.02%
IMVT	56 Neutral	$5.22B	-9.45	-95.93%	―	―	-27.70%
OCUL	55 Neutral	$2.40B	-8.01	-81.83%	―	-9.21%	-8.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IRON	51 Neutral	$2.92B	-15.11	-34.78%	―	―	-34.96%

Amicus Corporate Events

Amicus Therapeutics to Be Acquired by BioMarin

On December 19, 2025, Amicus Therapeutics agreed to be acquired by BioMarin Pharmaceutical in an all-cash transaction valuing Amicus at approximately $4.8 billion, or $14.50 per share, a premium of up to 58% over recent trading averages; following closing—expected in the second quarter of 2026 pending antitrust clearances and shareholder approval—Amicus will become a wholly owned BioMarin subsidiary, with Amicus shareholders cashed out and equity awards converted to cash. The deal will add Galafold and Pombiliti + Opfolda to BioMarin’s rare-disease portfolio, immediately boosting revenue growth, diversifying its enzyme therapy franchise and, according to the companies, becoming accretive to non-GAAP EPS within 12 months of closing and substantially accretive from 2027, financed via a mix of cash and about $3.7 billion of new debt; a $175 million termination fee and a suite of no-shop and fiduciary-out provisions govern competing bids, while a separate settlement of U.S. patent litigation over Galafold grants generic challengers licenses starting in 2037, effectively extending U.S. market exclusivity and bolstering the long-term value of the asset within BioMarin’s portfolio.

The most recent analyst rating on (FOLD) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Amicus stock, see the FOLD Stock Forecast page.